Japanese startup Ubie has scored $26.2 million in its first Series C funding round, participated by its new investors Norinchukin Capital Co., NVenture Capital Ltd., Dai-ichi Life Insurance Co., and Egg FORWARD. The round was also joined by its existing investor SUZUKEN Co.
This brings its total capital raised since inception to almost $60 million.
Founded in 2017, Ubie offers two AI-powered solutions: the Ubie AI Symptom Checker for patients and the AI Patient Intake for healthcare providers.
WHAT IT’S FOR
The startup plans to use its latest funding for its continued expansion across Japan and the United States.
Specifically, it will be used to accelerate collaborations with pharmaceutical companies, according to CEO and co-founder Dr Yoshinori Abe. To date, Ubie has partnered with over 20 pharmaceutical firms in Japan and other countries.
THE LARGER TREND
This funding event comes months after Ubie launched its web-based AI Symptom Checker in the US. This version comes with customised AI algorithms that take into account the country’s disease trends and other regional characteristics.
Ubie last held a fundraising event in 2020 where it raised about $19 million to scale its AI offerings.